JP2013534906A5 - - Google Patents

Download PDF

Info

Publication number: JP2013534906A5
Authority: JP; Japan
Prior art keywords: amino acid; alkyl; receptor; group; substitution
Prior art date: 2011-05-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2013510240A

Other languages

English (en)

Japanese (ja)

Other versions

JP6121323B2 (ja

JP2013534906A (ja

Filing date

2011-05-10

Publication date

2014-06-19

2011-05-10 Application filed filed Critical

2011-05-10 Priority claimed from PCT/US2011/035913 external-priority patent/WO2011143209A1/en

2013-09-09 Publication of JP2013534906A publication Critical patent/JP2013534906A/ja

2014-06-19 Publication of JP2013534906A5 publication Critical patent/JP2013534906A5/ja

2017-05-10 Application granted granted Critical

2017-05-10 Publication of JP6121323B2 publication Critical patent/JP6121323B2/ja

Status Active legal-status Critical Current

2031-05-10 Anticipated expiration legal-status Critical

Links

150000001413 amino acids Chemical group 0.000 claims 68
235000001014 amino acid Nutrition 0.000 claims 50
125000000217 alkyl group Chemical group 0.000 claims 21
150000001875 compounds Chemical class 0.000 claims 19
238000006467 substitution reaction Methods 0.000 claims 19
108060003199 Glucagon Proteins 0.000 claims 15
230000004048 modification Effects 0.000 claims 15
238000012986 modification Methods 0.000 claims 15
102000007399 Nuclear hormone receptor Human genes 0.000 claims 12
108020005497 Nuclear hormone receptor Proteins 0.000 claims 12
102000051325 Glucagon Human genes 0.000 claims 11
230000000694 effects Effects 0.000 claims 11
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical group C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 11
229960004666 glucagon Drugs 0.000 claims 11
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 9
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 9
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 8
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 8
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 8
125000006702 (C1-C18) alkyl group Chemical group 0.000 claims 7
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 7
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 7
-1 Ala Chemical compound 0.000 claims 6
238000012217 deletion Methods 0.000 claims 6
230000037430 deletion Effects 0.000 claims 6
125000002252 acyl group Chemical group 0.000 claims 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 4
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 4
CBQJSKKFNMDLON-JTQLQIEISA-N N-acetyl-L-phenylalanine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 CBQJSKKFNMDLON-JTQLQIEISA-N 0.000 claims 4
125000004429 atom Chemical group 0.000 claims 4
238000003776 cleavage reaction Methods 0.000 claims 4
125000000623 heterocyclic group Chemical group 0.000 claims 4
108090000765 processed proteins & peptides Proteins 0.000 claims 4
230000007017 scission Effects 0.000 claims 4
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 3
VBOQYPQEPHKASR-VKHMYHEASA-N L-homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 claims 3
102100040918 Pro-glucagon Human genes 0.000 claims 3
239000000556 agonist Substances 0.000 claims 3
108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 3
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 3
229910052739 hydrogen Inorganic materials 0.000 claims 3
238000001727 in vivo Methods 0.000 claims 3
239000003446 ligand Substances 0.000 claims 3
230000035945 sensitivity Effects 0.000 claims 3
125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
125000000041 C6-C10 aryl group Chemical group 0.000 claims 2
MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 claims 2
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims 2
108010063919 Glucagon Receptors Proteins 0.000 claims 2
102100040890 Glucagon receptor Human genes 0.000 claims 2
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims 2
OYIFNHCXNCRBQI-BYPYZUCNSA-N L-2-aminoadipic acid Chemical compound OC(=O)[C@@H](N)CCCC(O)=O OYIFNHCXNCRBQI-BYPYZUCNSA-N 0.000 claims 2
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 2
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
239000002253 acid Substances 0.000 claims 2
230000002378 acidificating effect Effects 0.000 claims 2
150000001408 amides Chemical group 0.000 claims 2
210000004899 c-terminal region Anatomy 0.000 claims 2
229910052799 carbon Inorganic materials 0.000 claims 2
150000001733 carboxylic acid esters Chemical class 0.000 claims 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
235000013477 citrulline Nutrition 0.000 claims 2
229960002173 citrulline Drugs 0.000 claims 2
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 claims 2
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
150000002148 esters Chemical group 0.000 claims 2
125000001072 heteroaryl group Chemical group 0.000 claims 2
238000003780 insertion Methods 0.000 claims 2
230000037431 insertion Effects 0.000 claims 2
239000000203 mixture Substances 0.000 claims 2
229910052760 oxygen Inorganic materials 0.000 claims 2
102000004196 processed proteins & peptides Human genes 0.000 claims 2
239000000651 prodrug Substances 0.000 claims 2
229940002612 prodrug Drugs 0.000 claims 2
125000006850 spacer group Chemical group 0.000 claims 2
229910052717 sulfur Inorganic materials 0.000 claims 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims 1
SNRCMWGPCHPRBP-YFKPBYRVSA-N (2s)-2-(hydroxyamino)-3-(1h-imidazol-5-yl)propanoic acid Chemical compound ON[C@H](C(O)=O)CC1=CNC=N1 SNRCMWGPCHPRBP-YFKPBYRVSA-N 0.000 claims 1
PSWSDQRXCOJSFC-FJXQXJEOSA-N (2s)-2-acetamido-3-(1h-imidazol-5-yl)propanoic acid;hydrate Chemical compound O.CC(=O)N[C@H](C(O)=O)CC1=CN=CN1 PSWSDQRXCOJSFC-FJXQXJEOSA-N 0.000 claims 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims 1
102100032187 Androgen receptor Human genes 0.000 claims 1
239000004475 Arginine Substances 0.000 claims 1
102100038495 Bile acid receptor Human genes 0.000 claims 1
125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 claims 1
HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
108010016626 Dipeptides Proteins 0.000 claims 1
102000004190 Enzymes Human genes 0.000 claims 1
108090000790 Enzymes Proteins 0.000 claims 1
102100038595 Estrogen receptor Human genes 0.000 claims 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims 1
102000003676 Glucocorticoid Receptors Human genes 0.000 claims 1
108090000079 Glucocorticoid Receptors Proteins 0.000 claims 1
IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 claims 1
101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims 1
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
208000001145 Metabolic Syndrome Diseases 0.000 claims 1
108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
102100021316 Mineralocorticoid receptor Human genes 0.000 claims 1
125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 claims 1
PSFABYLDRXJYID-VKHMYHEASA-N N-Methylserine Chemical compound CN[C@@H](CO)C(O)=O PSFABYLDRXJYID-VKHMYHEASA-N 0.000 claims 1
PSFABYLDRXJYID-UHFFFAOYSA-N N-methyl-DL-serine Natural products CNC(CO)C(O)=O PSFABYLDRXJYID-UHFFFAOYSA-N 0.000 claims 1
102100038494 Nuclear receptor subfamily 1 group I member 2 Human genes 0.000 claims 1
208000008589 Obesity Diseases 0.000 claims 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
108010001511 Pregnane X Receptor Proteins 0.000 claims 1
108091008680 RAR-related orphan receptors Proteins 0.000 claims 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
239000004473 Threonine Substances 0.000 claims 1
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
125000003342 alkenyl group Chemical group 0.000 claims 1
150000003973 alkyl amines Chemical class 0.000 claims 1
150000001412 amines Chemical class 0.000 claims 1
108010080146 androgen receptors Proteins 0.000 claims 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
125000003118 aryl group Chemical group 0.000 claims 1
239000003613 bile acid Substances 0.000 claims 1
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
235000012000 cholesterol Nutrition 0.000 claims 1
150000001886 cortisols Chemical class 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
229940039227 diagnostic agent Drugs 0.000 claims 1
239000000032 diagnostic agent Substances 0.000 claims 1
235000014113 dietary fatty acids Nutrition 0.000 claims 1
239000000539 dimer Substances 0.000 claims 1
125000002228 disulfide group Chemical group 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229960005309 estradiol Drugs 0.000 claims 1
229930182833 estradiol Natural products 0.000 claims 1
108010038795 estrogen receptors Proteins 0.000 claims 1
229960003399 estrone Drugs 0.000 claims 1
125000001033 ether group Chemical group 0.000 claims 1
229930195729 fatty acid Natural products 0.000 claims 1
239000000194 fatty acid Substances 0.000 claims 1
150000004665 fatty acids Chemical class 0.000 claims 1
208000010706 fatty liver disease Diseases 0.000 claims 1
239000012634 fragment Substances 0.000 claims 1
239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 1
108010015792 glycyllysine Proteins 0.000 claims 1
125000004404 heteroalkyl group Chemical group 0.000 claims 1
125000005842 heteroatom Chemical group 0.000 claims 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
125000005597 hydrazone group Chemical group 0.000 claims 1
150000001261 hydroxy acids Chemical class 0.000 claims 1
PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 claims 1
125000005647 linker group Chemical group 0.000 claims 1
102000004311 liver X receptors Human genes 0.000 claims 1
108090000865 liver X receptors Proteins 0.000 claims 1
108010054155 lysyllysine Proteins 0.000 claims 1
229930182817 methionine Natural products 0.000 claims 1
230000004770 neurodegeneration Effects 0.000 claims 1
208000015122 neurodegenerative disease Diseases 0.000 claims 1
229910052757 nitrogen Inorganic materials 0.000 claims 1
102000039446 nucleic acids Human genes 0.000 claims 1
108020004707 nucleic acids Proteins 0.000 claims 1
150000007523 nucleic acids Chemical class 0.000 claims 1
235000020824 obesity Nutrition 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
230000004962 physiological condition Effects 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
229920001184 polypeptide Polymers 0.000 claims 1
102000003998 progesterone receptors Human genes 0.000 claims 1
108090000468 progesterone receptors Proteins 0.000 claims 1
239000002096 quantum dot Substances 0.000 claims 1
102000003702 retinoic acid receptors Human genes 0.000 claims 1
108090000064 retinoic acid receptors Proteins 0.000 claims 1
150000003384 small molecules Chemical class 0.000 claims 1
231100000240 steatosis hepatitis Toxicity 0.000 claims 1
150000003431 steroids Chemical class 0.000 claims 1
229960003604 testosterone Drugs 0.000 claims 1
150000003568 thioethers Chemical class 0.000 claims 1
108090000721 thyroid hormone receptors Proteins 0.000 claims 1
102000004217 thyroid hormone receptors Human genes 0.000 claims 1
239000003053 toxin Substances 0.000 claims 1
231100000765 toxin Toxicity 0.000 claims 1
108700012359 toxins Proteins 0.000 claims 1
102000009310 vitamin D receptors Human genes 0.000 claims 1
108050000156 vitamin D receptors Proteins 0.000 claims 1
229910052727 yttrium Inorganic materials 0.000 claims 1

JP2013510240A 2010-05-13 2011-05-10 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド Active JP6121323B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US33443510P	2010-05-13	2010-05-13
US61/334,435		2010-05-13
US201161432077P	2011-01-12	2011-01-12
US61/432,077		2011-01-12
PCT/US2011/035913 WO2011143209A1 (en)	2010-05-13	2011-05-10	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity

Publications (3)

Publication Number	Publication Date
JP2013534906A JP2013534906A (ja)	2013-09-09
JP2013534906A5 true JP2013534906A5 (ru)	2014-06-19
JP6121323B2 JP6121323B2 (ja)	2017-05-10

Family

ID=44914673

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2013510240A Active JP6121323B2 (ja)	2010-05-13	2011-05-10	核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド

Country Status (12)

Country	Link
US (2)	US9127088B2 (ru)
EP (1)	EP2569000B1 (ru)
JP (1)	JP6121323B2 (ru)
KR (1)	KR20130062931A (ru)
CN (1)	CN103079587B (ru)
AR (1)	AR081043A1 (ru)
BR (1)	BR112012028704A2 (ru)
CA (1)	CA2797095A1 (ru)
ES (1)	ES2661228T3 (ru)
MX (1)	MX2012013001A (ru)
RU (1)	RU2604067C2 (ru)
WO (1)	WO2011143209A1 (ru)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101534846B (zh)	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
ES2628063T3 (es)	2007-01-05	2017-08-01	Indiana University Research And Technology Corporation	Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
JP6017754B2 (ja)	2007-02-15	2016-11-02	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴン／ｇｌｐ−１受容体コアゴニスト
KR20160061439A (ko)	2007-03-28	2016-05-31	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	스티칭된 폴리펩티드
AU2008318986B2 (en)	2007-10-30	2014-12-04	Indiana University Research And Technology Corporation	Glucagon antagonists
ES2558155T3 (es)	2007-10-30	2016-02-02	Indiana University Research And Technology Corporation	Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
MX2010012695A (es)	2008-06-17	2011-03-15	Univ Indiana Res & Tech Corp	Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
CN103641907A (zh)	2008-06-17	2014-03-19	印第安纳大学研究及科技有限公司	胰高血糖素/glp-1受体共激动剂
JP6108659B2 (ja)	2008-06-17	2017-04-05	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
MX2011006524A (es)	2008-12-19	2011-08-17	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida.
WO2010148089A1 (en)	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
MX2012013001A (es)	2010-05-13	2013-02-26	Univ Indiana Res & Tech Corp	Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
BR112012028707A2 (pt)	2010-05-13	2019-09-24	Univ Indiana Res & Tech Corp	composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
EP2588126A4 (en)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
SI2603600T1 (sl)	2010-08-13	2019-04-30	Aileron Therapeutics, Inc.	Peptidomimetični makrocikli
WO2012088116A2 (en)	2010-12-22	2012-06-28	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting gip receptor activity
CN102643339B (zh) *	2011-02-21	2014-04-09	天津药物研究院	一种glp-1类似物、制备方法及其应用
US8729017B2 (en)	2011-06-22	2014-05-20	Indiana University Research And Technology Corporation	Glucagon/GLP-1 receptor co-agonists
WO2012177443A2 (en)	2011-06-22	2012-12-27	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
AU2012326026B2 (en)	2011-10-18	2017-04-13	Aileron Therapeutics, Inc.	Peptidomimetic macrocyles
JP6324315B2 (ja) *	2011-11-17	2018-05-16	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルココルチコイド受容体の活性を示すグルカゴンスーパーファミリーのペプチド
AU2013221433B2 (en)	2012-02-15	2018-01-18	Aileron Therapeutics, Inc.	Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en)	2012-02-15	2021-05-25	Aileron Therapeutics, Inc.	Peptidomimetic macrocycles
JP2015514070A (ja)	2012-03-21	2015-05-18	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	Ｔｆｐｉ阻害剤および使用方法
SG11201407860PA (en) *	2012-06-14	2014-12-30	Sanofi Sa	Exendin-4 peptide analogues
TR201808818T4 (tr) *	2012-06-21	2018-07-23	Novo Nordisk As	Gip reseptör aktivitesi sergileyen glukagon analogları.
TWI599575B (zh)	2012-06-21	2017-09-21	印第安納大學科技研究公司	表現ｇｉｐ受體活性之胰高血糖素類似物
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SI3342785T1 (sl)	2012-10-11	2020-02-28	Daiichi Sankyo Company, Limited	Povezovalci za konjugate protitelesa in zdravila
WO2014061277A1 (ja)	2012-10-19	2014-04-24	第一三共株式会社	親水性構造を含むリンカーで結合させた抗体－薬物コンジュゲート
JP6526563B2 (ja)	2012-11-01	2019-06-05	エイルロンセラピューティクス，インコーポレイテッド	二置換アミノ酸ならびにその調製および使用の方法
TWI674270B (zh)	2012-12-11	2019-10-11	英商梅迪繆思有限公司	用於治療肥胖之升糖素與glp-1共促效劑
KR20150096433A (ko)	2012-12-21	2015-08-24	사노피	이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제
US9714277B2 (en)	2013-03-14	2017-07-25	Medimmune Limited	Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
CA2909941A1 (en)	2013-04-24	2014-10-30	Salk Institute For Biological Studies	Vitamin d receptor/smad genomic circuit gates fibrotic response
WO2014197680A1 (en) *	2013-06-05	2014-12-11	Salk Institute For Biological Studies	Vitamin d receptor agonists to treat diseases involving cxcl12 activity
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086733A1 (en)	2013-12-13	2015-06-18	Sanofi	Dual glp-1/glucagon receptor agonists
EP3080152A1 (en)	2013-12-13	2016-10-19	Sanofi	Non-acylated exendin-4 peptide analogues
EP3080150B1 (en)	2013-12-13	2018-08-01	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
AR098616A1 (es)	2013-12-18	2016-06-01	Lilly Co Eli	Péptido para el tratamiento de hipoglicemia severa
RU2743077C2 (ru)	2013-12-25	2021-02-15	Дайити Санкио Компани, Лимитед	Конъюгат анти-trop2 антитело-лекарственное средство
HUE057464T2 (hu)	2014-01-31	2022-05-28	Daiichi Sankyo Co Ltd	Anti-HER2 antitest-hatóanyag konjugátum
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
JP6612738B2 (ja)	2014-04-10	2019-11-27	第一三共株式会社	抗ｈｅｒ２抗体−薬物コンジュゲート
IL311108A (en)	2014-04-10	2024-04-01	Daiichi Sankyo Co Ltd	Preparation method of drug conjugate - anti-HER3 antibody
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
MX2017003797A (es)	2014-09-24	2017-06-15	Aileron Therapeutics Inc	Macrociclos peptidomimeticos y usos de los mismos.
CN107206030B (zh) *	2014-12-08	2020-11-17	Gi生物群系公司	包含生酸拟杆菌作为有效成分的用于预防或治疗代谢性疾病的药学组合物
JP2018516844A (ja)	2015-03-20	2018-06-28	エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	ペプチド模倣大環状分子およびその使用
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TWI726889B (zh)	2015-06-10	2021-05-11	英商梅迪繆思有限公司	蛋白酶抗性之脂化肽
IL290959B2 (en)	2015-06-29	2023-04-01	Daiichi Sankyo Co Ltd	Preparations containing antibody-drug conjugates and methods for their production
AR105284A1 (es)	2015-07-10	2017-09-20	Sanofi Sa	Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN108602894A (zh) *	2015-10-30	2018-09-28	纽约州立大学研究基金会	胃泌酸调节素类似物及其制备和使用方法
PL3393496T3 (pl)	2015-12-23	2024-04-22	The Johns Hopkins University	Długo działający agonista glp-1r jako terapia stanów neurologicznych i neurodegeneracyjnych
CN106046145B (zh)	2016-04-22	2022-11-04	深圳市图微安创科技开发有限公司	Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
EP3452049A4 (en) *	2016-05-06	2020-01-08	Ionis Pharmaceuticals, Inc.	GLP-1 RECEPTOR LIGAND PART CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF
US20190290772A1 (en) *	2016-06-02	2019-09-26	Indiana University Research And Technology Corporation	Glucagon-like peptide-1-t3 conjugates
US20190388510A1 (en) *	2016-06-02	2019-12-26	Indiana University Research And Technology Corporation	Glucagon-t3 conjugates
WO2017210242A1 (en) *	2016-06-02	2017-12-07	Indiana University Research And Technology Corporation	Insulin-nuclear hormone conjugates
TWI862473B (zh)	2016-12-12	2024-11-21	日商第一三共股份有限公司	抗體-藥物結合物與免疫檢查點抑制劑之組合、以及醫藥組成物之用途
KR102537651B1 (ko)	2017-01-17	2023-05-26	다이이찌 산쿄 가부시키가이샤	항 gpr20 항체 및 항 gpr20 항체-약물 콘쥬게이트
TW202504644A (zh)	2017-05-15	2025-02-01	日商第一三共股份有限公司	抗體－藥物結合物之用途
WO2019023149A1 (en)	2017-07-24	2019-01-31	Salk Institute For Biological Studies	USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
CN111051330A (zh)	2017-08-31	2020-04-21	第一三共株式会社	抗体-药物缀合物的改进制备方法
IL272964B2 (en)	2017-08-31	2024-02-01	Daiichi Sankyo Co Ltd	Method for producing antibody-drug conjugate
EP3788063B1 (en)	2018-05-04	2023-08-09	Novo Nordisk A/S	Gip derivatives and uses thereof
EP4257611A3 (en)	2018-05-18	2024-03-06	Glycotope GmbH	Anti-muc1 antibody
BR112021001509A2 (pt)	2018-07-31	2021-04-27	Daiichi Sankyo Company, Limited	agente terapêutico para um tumor de cérebro metastásico
DK3897738T5 (da) *	2018-12-21	2024-08-05	Sapreme Tech Bv	Saponin-konjugater
CN111825758B (zh) *	2019-04-19	2024-11-22	上海翰森生物医药科技有限公司	Glp-1和gip共激动剂化合物
WO2023168249A2 (en) *	2022-03-02	2023-09-07	Boyce Thompson Institute For Plant Research, Inc.	Cysteamides, therapeutic compositions thereof, and related methods

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275152A (en)	1977-02-03	1981-06-23	Eastman Kodak Company	Hydrolysis of protein-bound cholesterol esters
PT83613B (en)	1985-10-28	1988-11-21	Lilly Co Eli	Process for the selective chemical removal of a protein amino-terminal residue
AU597574B2 (en)	1986-03-07	1990-06-07	Massachusetts Institute Of Technology	Method for enhancing glycoprotein stability
EP0628570A1 (en)	1989-02-17	1994-12-14	Chiron Mimotopes Pty. Ltd.	Method for the use and synthesis of peptides
CA2024855C (en)	1990-09-07	1997-12-09	Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee	Process and intermediates for producing glucagon
JPH04145099A (ja)	1990-10-05	1992-05-19	Sanwa Kagaku Kenkyusho Co Ltd	Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途
US5510459A (en)	1991-01-17	1996-04-23	Zymogenetics, Inc.	Glucagon antagonists
JP3266311B2 (ja)	1991-05-02	2002-03-18	生化学工業株式会社	新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
US5359030A (en)	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5480867A (en)	1993-12-29	1996-01-02	The Rockefeller University	Glucagon analogs with serine replacements
US5512549A (en)	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5691309A (en)	1995-01-31	1997-11-25	Eli Lilly And Company	Anti-obesity proteins
US5869602A (en)	1995-03-17	1999-02-09	Novo Nordisk A/S	Peptide derivatives
DE19530865A1 (de)	1995-08-22	1997-02-27	Michael Dr Med Nauck	Wirkstoff sowie Mittel zur parenteralen Ernährung
JPH10508322A (ja)	1995-10-12	1998-08-18	スーパーゲン，インコーポレイティド	５βステロイドのリポソーム配合物
JP2001503963A (ja)	1996-02-06	2001-03-27	イーライ・リリー・アンド・カンパニー	糖尿病治療
JP2001505872A (ja)	1996-09-09	2001-05-08	ジーランドファーマシューティカルズアクティーゼルスカブ	α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ
UA65549C2 (ru) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Применение аналогов и производных glp-1 для периферического введения для борьбы с ожирением
AU5518798A (en)	1996-12-03	1998-06-29	Trustees Of Boston University	Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
EP1950224A3 (en)	1998-03-09	2008-12-17	Zealand Pharma A/S	Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US20030236190A1 (en)	1998-09-02	2003-12-25	Renuka Pillutla	Isulin and IGF-1 receptor agonists and antagonists
JP2002526554A (ja)	1998-10-07	2002-08-20	メディカルカレッジオブジョージアリサーチインスティチュート，インコーポレイテッド	骨親和性ホルモンとして用いられるグルコース依存性インスリン親和性ペプチド
EP1147094A1 (en)	1999-01-15	2001-10-24	Novo Nordisk A/S	Non-peptide glp-1 agonists
GB0404124D0 (en)	2004-02-25	2004-03-31	Univ Ulster	Antagonists of GIP
DE60012721D1 (de)	1999-03-29	2004-09-09	Uutech Ltd	Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
US7601691B2 (en)	1999-05-17	2009-10-13	Conjuchem Biotechnologies Inc.	Anti-obesity agents
EA003922B1 (ru)	1999-05-17	2003-10-30	Конджачем, Инк.	Продолжительно действующие инсулинотропные пептиды
AU2001257278A1 (en)	2000-04-27	2001-11-07	Bionebraska, Inc.	Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose
US6677136B2 (en)	2000-05-03	2004-01-13	Amgen Inc.	Glucagon antagonists
JP2004503565A (ja)	2000-06-14	2004-02-05	サイトヴァックス・バイオテクノロジーズ・インコーポレーテッド	構造特異的ペプチドを生産するためのコイルドコイル構造的骨格の使用
CN100469791C (zh)	2000-06-16	2009-03-18	伊莱利利公司	胰高血糖素样肽-1类似物
US20030204063A1 (en)	2000-08-02	2003-10-30	Denis Gravel	Modified biological peptides with increased potency
US20020045572A1 (en)	2000-08-15	2002-04-18	Cpd, Llc	Method of treating the syndrome of type 2 diabetes in humans
US6846831B2 (en)	2000-08-15	2005-01-25	Cpd, Llc	Method of treating the syndrome of lipodystrophy
US6528520B2 (en)	2000-08-15	2003-03-04	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
US6262062B1 (en)	2000-08-15	2001-07-17	Cpd, Llc	Method of treating the syndrome of coronary heart disease risk factors in humans
EP1324779B1 (en)	2000-09-29	2011-07-20	Schering Corporation	Pegylated interleukin-10
WO2002048192A2 (en)	2000-12-13	2002-06-20	Eli Lilly And Company	Amidated glucagon-like peptide-1
EP1411968B1 (en)	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp-1 exendin-4 peptide analogs and uses thereof
US20040002468A1 (en)	2001-08-08	2004-01-01	Genzyme Corporation	Methods of treating diabetes and other blood sugar disorders
AU2002322403A1 (en)	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
CN1635900A (zh)	2001-08-28	2005-07-06	伊莱利利公司	Glp－1和基础胰岛素的预混合物
GB0121709D0 (en)	2001-09-07	2001-10-31	Imp College Innovations Ltd	Food inhibition agent
AR036711A1 (es)	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
US7041646B2 (en)	2001-10-05	2006-05-09	Bayer Pharmaceuticals Corporation	Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
YU31004A (sh)	2001-10-18	2006-08-17	Bristol-Myers Squibb Company	Mimetici humanog glukagonu sličnog peptida-1 i njihova upotreba u lečenju dijabetesa i srodnih stanja
WO2003035099A1 (en)	2001-10-19	2003-05-01	Eli Lilly And Company	Biphasic mixtures of glp-1 and insulin
EP1461069A2 (en)	2001-12-29	2004-09-29	Novo Nordisk A/S	Combined use of a glp-1 compound and another drug for treating dyslipidemia
EP1585959A4 (en)	2002-01-08	2007-11-14	Lilly Co Eli	PEPTIDE-1 ANALOGUES OF EXTENSION GLUCAGON TYPE
US20030232761A1 (en)	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
US20060252916A1 (en)	2002-06-04	2006-11-09	Eli Lilly And Company	Modified glucagon-like peptide-1 analogs
EP1515746A2 (en)	2002-06-11	2005-03-23	Eisai Co. Ltd	Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity
CA2489323A1 (en)	2002-06-15	2003-12-24	Enteromed, Inc.	Treatment of non-alcoholic fatty liver disease
CA2497794A1 (en)	2002-09-06	2004-03-18	Bayer Pharmaceuticals Corporation	Modified glp-1 receptor agonists and their pharmacological methods of use
US7192922B2 (en)	2002-11-19	2007-03-20	Allegheny-Singer Research Institute	Method of treating left ventricular dysfunction
JP2006524039A (ja)	2003-01-09	2006-10-26	マクロジェニクス，インコーポレーテッド	変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
WO2004067548A2 (en)	2003-01-31	2004-08-12	Theratechnologies Inc.	Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1626981A4 (en)	2003-03-04	2006-11-22	Biorexis Pharmaceutical Corp	PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
KR100733940B1 (ko)	2003-03-19	2007-06-29	일라이 릴리 앤드 캄파니	폴리에틸렌 글리콜이 연결된 ｇｌｐ-1 화합물
PT1620118E (pt)	2003-04-08	2014-10-16	Yeda Res & Dev	Fármacos peguilados de modo reversível
TWI353991B (en)	2003-05-06	2011-12-11	Syntonix Pharmaceuticals Inc	Immunoglobulin chimeric monomer-dimer hybrids
ATE549028T1 (de)	2003-05-15	2012-03-15	Tufts College	Stabile analoga von glp-1
CA2527743A1 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
WO2004105790A1 (en)	2003-06-03	2004-12-09	Novo Nordisk A/S	Stabilized pharmaceutical peptide compositions
WO2005000892A2 (en)	2003-06-12	2005-01-06	Eli Lilly And Company	Glp-1 analog fusion plroteins
WO2004111078A2 (en)	2003-06-18	2004-12-23	Theratechnologies Inc.	Compounds that modulate the glucagon response and uses thereof
WO2005027978A2 (en)	2003-09-19	2005-03-31	Novo Nordisk A/S	Albumin-binding derivatives of therapeutic peptides
US7364875B2 (en)	2003-10-30	2008-04-29	Cresent Innovations, Inc.	Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight
CA2549582A1 (en)	2003-12-18	2005-06-30	Novo Nordisk A/S	Novel glp-1 compounds
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
US20080318837A1 (en)	2003-12-26	2008-12-25	Nastech Pharmaceutical Company Inc.	Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
MX2007007602A (es)	2004-12-22	2007-12-07	Johnson & Johnson	Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos.
JP2008530130A (ja)	2005-02-11	2008-08-07	アミリン・ファーマシューティカルズ，インコーポレイテッド	Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
JP2008533104A (ja)	2005-03-18	2008-08-21	ノボノルディスクアクティーゼルスカブ	Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
WO2006121904A1 (en)	2005-05-06	2006-11-16	Bayer Pharmaceuticals Corporation	Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use
EA012442B1 (ru)	2005-05-13	2009-10-30	Эли Лилли Энд Компани	Пегилированные соединения glp-1
CA2612063A1 (en)	2005-06-13	2006-12-21	Imperial Innovations Limited	Oxyntomodulin analogues and their effects on feeding behaviour
EP1922336B1 (en)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
US20090170762A1 (en)	2005-09-08	2009-07-02	Uutech Limited	Treatment of Diabetes Related Obesity
EP1937716A2 (en)	2005-09-08	2008-07-02	Uutech Limited	Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
JP2009507844A (ja)	2005-09-08	2009-02-26	トラスティーズオブタフツカレッジ	安定化ｇｌｐ−１類似体
US7846445B2 (en)	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
CN101534846B (zh)	2005-11-07	2014-11-05	印第安纳大学研究及科技有限公司	显示生理学溶解性和稳定性的胰高血糖素类似物
WO2007100535A2 (en)	2006-02-22	2007-09-07	Merck & Co., Inc.	Oxyntomodulin derivatives
US20090054305A1 (en)	2006-03-15	2009-02-26	Novo Nordisk A/S	Mixtures of Amylin and Insulin
US20090186817A1 (en)	2006-03-21	2009-07-23	Amylin Pharmaceuticals, Inc.	Peptide-peptidase inhibitor conjugates and methods of using same
EP2573111A1 (en)	2006-04-20	2013-03-27	Amgen Inc.	GLP-1 compounds
AU2007249736A1 (en)	2006-05-15	2007-11-22	Wisconsin Alumni Research Foundation	Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr)	2006-06-07	2008-09-05	Sapelem Soc Par Actions Simpli	Appareil de manutention de charge
WO2008022015A2 (en)	2006-08-11	2008-02-21	Trustees Of Tufts College	Retro-inverso incretin analogues, and methods of use thereof
JP5399244B2 (ja)	2006-08-17	2014-01-29	アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー	選択可能な特性を持つｄｐｐ−ｉｖ耐性ｇｉｐハイブリッドポリペプチド
EP2057189B1 (en)	2006-08-25	2013-03-06	Novo Nordisk A/S	Acylated exendin-4 compounds
EP2069396B1 (en)	2006-09-08	2015-10-21	Ambrx, Inc.	Modified human plasma polypeptide or fc scaffolds and their uses
EP2102355B1 (en)	2006-12-14	2016-03-02	Bolder Biotechnology, Inc.	Long acting proteins and peptides and methods of making and using the same
ES2628063T3 (es)	2007-01-05	2017-08-01	Indiana University Research And Technology Corporation	Análogos de glucagón que muestran una mayor solubilidad en tampones de pH fisiológicos
JP6017754B2 (ja)	2007-02-15	2016-11-02	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	グルカゴン／ｇｌｐ−１受容体コアゴニスト
AU2008287340A1 (en)	2007-08-15	2009-02-19	Amunix, Inc.	Compositions and methods for modifying properties of biologically active polypeptides
ES2672770T3 (es)	2007-09-05	2018-06-18	Novo Nordisk A/S	Derivados del péptido-1 similar al glucagón y su uso farmacéutico
CN101842386A (zh)	2007-09-05	2010-09-22	诺沃-诺迪斯克有限公司	截短的glp-1衍生物和它们的治疗用途
EP2650006A1 (en)	2007-09-07	2013-10-16	Ipsen Pharma S.A.S.	Analogues of exendin-4 and exendin-3
WO2009034117A1 (en)	2007-09-11	2009-03-19	Novo Nordisk A/S	Mixture comprising an amylin peptide and a protracted insulin
EP2036923A1 (en)	2007-09-11	2009-03-18	Novo Nordisk A/S	Improved derivates of amylin
EP2036539A1 (en)	2007-09-11	2009-03-18	Novo Nordisk A/S	Stable formulations of amylin and its analogues
AU2008318986B2 (en)	2007-10-30	2014-12-04	Indiana University Research And Technology Corporation	Glucagon antagonists
ES2558155T3 (es) *	2007-10-30	2016-02-02	Indiana University Research And Technology Corporation	Compuestos que muestran actividad antagonista de glucacón y agonista de GLP-1
EP2209780B1 (en)	2007-11-01	2014-01-01	Bristol-Myers Squibb Company	Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
WO2009099763A1 (en)	2008-01-30	2009-08-13	Indiana University Research And Technology Corporation	Ester-based peptide prodrugs
DK2596805T3 (da)	2008-02-01	2021-12-13	Ascendis Pharma As	Prodrug omfattende et lægemiddel-linker-konjugat
CN103641907A (zh)	2008-06-17	2014-03-19	印第安纳大学研究及科技有限公司	胰高血糖素/glp-1受体共激动剂
JP6108659B2 (ja)	2008-06-17	2017-04-05	インディアナユニバーシティーリサーチアンドテクノロジーコーポレーションＩｎｄｉａｎａＵｎｉｖｅｒｓｉｔｙＲｅｓｅａｒｃｈＡｎｄＴｅｃｈｎｏｌｏｇｙＣｏｒｐｏｒａｔｉｏｎ	代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
MX2010012695A (es)	2008-06-17	2011-03-15	Univ Indiana Res & Tech Corp	Analogos de glucagon que exhiben solubilidad y estabilidad aumentadas en soluciones reguladoras de ph fisiologico.
EP2303890A4 (en)	2008-06-19	2012-04-11	Progenics Pharm Inc	INHIBITORS OF PHOSPHATIDYLINOSITE-3-KINASE
AU2009303905B2 (en)	2008-10-15	2015-01-22	Intarcia Therapeutics, Inc.	Highly concentrated drug particles, formulations, suspensions and uses thereof
WO2010080605A1 (en)	2008-12-19	2010-07-15	Indiana University Research And Technology Corporation	Dipeptide linked medicinal agents
MX2011006524A (es)	2008-12-19	2011-08-17	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida.
WO2010096052A1 (en)	2009-02-19	2010-08-26	Merck Sharp & Dohme Corp.	Oxyntomodulin analogs
WO2010148089A1 (en)	2009-06-16	2010-12-23	Indiana University Research And Technology Corporation	Gip receptor-active glucagon compounds
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
WO2011075393A2 (en)	2009-12-18	2011-06-23	Indiana University Research And Technology Corporation	Glucagon/glp-1 receptor co-agonists
AR079345A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina
AR079344A1 (es)	2009-12-22	2012-01-18	Lilly Co Eli	Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
KR20120123443A (ko)	2010-01-27	2012-11-08	인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션	대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
AR080592A1 (es)	2010-03-26	2012-04-18	Lilly Co Eli	Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
MX2012013001A (es)	2010-05-13	2013-02-26	Univ Indiana Res & Tech Corp	Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas.
BR112012028707A2 (pt)	2010-05-13	2019-09-24	Univ Indiana Res & Tech Corp	composto de glucagon da superfamília de peptídeos exibindo atividade do receptor g com proteína acoplada, pró farmaco, dímero ou multímro, composição farmacêutica que o compreendem e método de administração do mesmo.
EP2588126A4 (en)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
WO2011163473A1 (en)	2010-06-25	2011-12-29	Indiana University Research And Technology Corporation	Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers

2011
- 2011-05-10 MX MX2012013001A patent/MX2012013001A/es active IP Right Grant
- 2011-05-10 WO PCT/US2011/035913 patent/WO2011143209A1/en active Application Filing
- 2011-05-10 EP EP11781137.2A patent/EP2569000B1/en not_active Not-in-force
- 2011-05-10 CN CN201180037112.9A patent/CN103079587B/zh not_active Expired - Fee Related
- 2011-05-10 US US13/697,018 patent/US9127088B2/en not_active Expired - Fee Related
- 2011-05-10 RU RU2012153755/04A patent/RU2604067C2/ru not_active IP Right Cessation
- 2011-05-10 BR BR112012028704A patent/BR112012028704A2/pt not_active IP Right Cessation
- 2011-05-10 KR KR20127029663A patent/KR20130062931A/ko not_active Ceased
- 2011-05-10 CA CA 2797095 patent/CA2797095A1/en not_active Abandoned
- 2011-05-10 JP JP2013510240A patent/JP6121323B2/ja active Active
- 2011-05-10 ES ES11781137.2T patent/ES2661228T3/es active Active
- 2011-05-12 AR ARP110101649 patent/AR081043A1/es unknown
2015
- 2015-07-24 US US14/808,668 patent/US9783592B2/en not_active Expired - Fee Related

Publication	Publication Date	Title
JP2013534906A5 (ru)	2014-06-19
JP2013533849A5 (ru)	2014-06-26
CA2797095A1 (en)	2011-11-17	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
RU2012153753A (ru)	2014-06-20	Пептиды глюкагонового суперсемейства, обладающие активностью в отношении сопряженных с g-белком рецепторов
RU2014117678A (ru)	2015-12-27	Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
JP2015504431A5 (ru)	2016-01-14
JP6538645B2 (ja)	2019-07-03	インスリン‐インクレチン複合物
ES2822994T3 (es)	2021-05-05	Conjugados de incretina-insulina
JP6179864B2 (ja)	2017-08-16	グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
RU2580317C2 (ru)	2016-04-10	Пептидные пролекарства, принадлежащие к суперсемейству амид-содержащих глюкагонов
JP2012512903A5 (ru)	2013-02-21
JP2011520847A (ja)	2011-07-21	遅効型ｙ２及び／又はｙ４レセプターアゴニスト
WO2017210242A1 (en)	2017-12-07	Insulin-nuclear hormone conjugates
TW201143790A (en)	2011-12-16	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
HK1183824A (en)	2014-01-10	Amide based glucagon superfamily peptide prodrugs
HK1183240A (en)	2013-12-20	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity